Local-regional therapy plus ICIs, chemotherapy, and lenvatinib versus ICIs plus chemotherapy in advanced intrahepatic cholangiocarcinoma: a multicenter study

Key Points

• Overall survival increases with the addition of local-regional therapy and lenvatinib, showing a significant advantage in treatment.
• In the cohort, median overall survival was 16.5 months compared to 12.3 months in the ICIs and chemotherapy group.
• Observational analysis across multiple centers highlights treatment effectiveness in advanced intrahepatic cholangiocarcinoma.
• Findings indicate the potential for combining therapies, calling for further exploration in clinical settings.